MP0310
Protein / enzyme therapeutic
Evidence outlook · program status
On hold (2022-08-25), as a strategic decision by the sponsor
Amgen returned global rights in 2022; Molecular Partners completed Phase 1 enrollment and stated that no additional studies were planned and no additional internal investment was planned, pending business development. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04049903 NCT04049903 · Advanced Solid Tumors Registry: NCT04049903 | 1 | Incidence of Adverse Events (AEs) (From signing of informed consent form (ICF) until 10 weeks following the last dose or start of new anticancer therapy.); Incidence of dose-limiting toxicities (DLTs) (First 21 days of dosing.); Maximum tolerated dose (MTD) or a tolerated dose below MTD (if MTD is not reached) (From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.); Recommended expansion dose (RED) (From signing of ICF until 10 weeks following the last dose or start of new anticancer therapy.) 2022-06-27 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Advanced Solid Tumors: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| MP0310: this drug | Phase 1 | Protein / enzyme therapeutic | FAP x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4956 | Phase 1/2(overall) | Small molecule | POLQ (DNA polymerase theta) | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986517 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986548 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-6768 | Phase 1/2 | Undisclosed | Fibroblast Activation Protein (FAP) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8364 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Palacaparib | Phase 1/2(overall) | Small molecule | PARP1 inhibitor (next-gen) | not yet graded | No reviewed efficacy summary in this indication | |
| REGN10597 | Phase 1/2 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1681 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4298 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4375 | Phase 1/2 | Antibody–drug conjugate | Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4610 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7787 | Phase 1/2 | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-9803 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-188 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-505 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-253 | Phase 1 | Biologic (subtype unspecified) | c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986500 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5533524 | Phase 1 | Antibody–drug conjugate | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-6093 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-87890387 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-89862175 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3821 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4685 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4849 | Phase 1 | Antibody–drug conjugate | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7782 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-168 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| YS-ON-001 | Phase 1 | Biologic (subtype unspecified) | TLR3 (poly I:C adjuvant) | not yet graded | No reviewed efficacy summary in this indication | |
| 225Ac-ETN029 | —(overall) | Radioligand Therapy (actinium-225) | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| AAA614 | —(overall) | Radioligand Therapy | Fibroblast Activation Protein (FAP) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5863 | —(overall) | Multispecific antibody | Claudin 18.2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD9793 | —(overall) | Multispecific antibody | Glypican-3 (GPC3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986506 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GCJ904 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5460025 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08032560 | —(overall) | Small molecule | KAT6A/KAT6B and KAT7 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08046044 | —(overall) | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| RG6505 | —(overall) | Undisclosed | RAS (pan-RAS, RAS-mutant tumors) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6620 | —(overall) | Undisclosed | KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| RG6648 | —(overall) | Antibody–drug conjugate | c-MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.